Terry A. Vik

Terry A. Vik, MD

Professor of Clinical Pediatrics

Bio

Dr. Terry Vik is a Professor of Pediatrics and has been a faculty member of Indiana University School of Medicine and Riley Hospital for Children for over 25 years. Dr. Vik is the Director of our Childhood Cancer Survivor Program as well as Associate Director of the Fellowship Program in Pediatric Hematology-Oncology. He received his medical degree from Johns Hopkins University, completed Residency at UCLA and Fellowship at The Children’s Hospital/ Dana-Farber Cancer Institute in Boston. Dr. Vik is instrumental in fostering the Childhood Cancer Treatment Program at our sister hospital in Eldoret, Kenya, as well as facilitating research with childhood cancer survivors. When not working on various job-related projects, Dr. Vik enjoys soccer, Outdoor activities with his family and dogs, and travel.

Key Publications

 

Vik TA. Pfluger T. Kadota R. Castel V. Tulchinsky M. Farto JC. Heiba S. Serafini A. Tumeh S. Khutoryansky N. Jacobson AF. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatric Blood & Cancer. 52(7):784-90, 2009.

 

 

 

Spunt, SL, Grupp, SA, Vik, TA, Santana, VM, Greenblatt, DJ, Clancy, J. Berkenblit, A, Krygowski, M, Ananthakrishnan, R, Boni, JP, and Gilbertson, RJ. Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors. J Clin Oncol. 29(21):2933-40, 2011.

 

 

 

Pradhan, KR, Mund, JA Johnson, C, Vik, TA, Ingram, DA, and Case, J. Polychromatic Flow Cytometry Identifies Novel Subsets of Circulating Cells with Angiogenic Potential in Pediatric Solid Tumors. Cytometry Part B, 80B:335-338, 2011.

 

 

 

Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis  type 1: a phase 2 trial. Lancet Oncol. 13:1218-24.  2012.

 

 

 

Mahajerin, A., Obasaju P., Eckert G., Vik, TA., Mehta R., and Heiny M. Thrombophilia testing in children: a 7 year experience. Pediatric Blood and Cancer. 61:523-527, 2014.

 

 

 

Jayachandran D, Rundell AE, Hannemann RE, Vik TA, Ramkrishna D. Optimal

 

chemotherapy for leukemia: a model-based strategy for individualized treatment.

 

PloS one. 2014; 9(10):e109623.

 

 

 

Moormann AM, Skiles JL, Otieno JA, Buckle GC, Vik TA. Optimal management of endemic Burkitt lymphoma: a holistic approach mindful of limited resources.

 

Blood and Lymphatic Cancer: Targets and Therapy . 2014; 4:91-99.

 

 

 

Njuguna F, Martijn H, Kuremu R, Saula P, Kirtika P, Olbara G, Langat S, Martin S, Skiles J, Vik T, Kaspers G, Mostert S. Wilms Tumor Treatment Outcomes: Perspectives From a Low-Income Setting

 

JGO. 2016; :JGO.2016.005389.

 

 

 

Njuguna F, Martijn H, Langat S, Musimbi J, Muliro H, Skiles J, Vik T, Sitaresmi

 

MN, van de Ven PM, Kaspers GJ, Mostert S. Factors influencing time to diagnosis and treatment among pediatric oncology patients in Kenya. Pediatric hematology and oncology. 2016; 33(3):186-99.

 

 

 

Buckle G, Maranda L, Skiles J, Ong'echa JM, Foley J, Epstein M, Vik TA, Schroeder A, Lemberger J, Rosmarin A, Remick SC, Bailey JA, Vulule J, Otieno JA, Moormann AM. Factors influencing survival among Kenyan children diagnosed with endemic Burkitt lymphoma between 2003 and 2011: A historical cohort study. International journal of cancer. 2016; 139(6):1231-40.

 

Connect


(317) 944-8784 


Ped-Hematology/Oncology
705 Riley Hospital Drive ROC 4340
Indianapolis, IN 46202


  

Titles & Appointments

  • Director, Childhood Cancer Survivor Program